The market for GSK-3 inhibitors is experiencing a surge in growth, driven by cutting-edge programs in mid- and late-stage development rather than traditional drugs like lithium. These innovative programs have the potential to revolutionize treatment approaches for various diseases. With a focus on more targeted therapies, significant advancements are expected to emerge from ongoing trials in the next few years, shaping the future of GSK-3 inhibitors in the medical landscape.